Kinase activity blocks the transmission of the VEGF/VEGFR‐2 signaling pathway and inhibits tumor angiogenesis, thereby inhibiting tumor growth.25, 26 At present, apatinib is mainly used in the treatment of advanced gastric cancer as a third‐line or higher treatment.27 Furthermore, a series of clinical trials of apatinib in the treatment of advanced lung cancer initially confirmed that apatinib can effectively slow the growth of lung cancer. Here, KDR is linked to lung cancer.